Joe Kong retweeted
WE'RE HIRING! ☀️ Clemons Lab @PeterMacRes is expanding and looking for a talented postdoc or research assistant to help investigate immunotherapies in gastro-oesophageal cancers. If you have 🐁 experience and interest in cancer biology, join our team! Details/apply 👇 Please RT!
Joe Kong retweeted
In the BJS April issue: Lateral pelvic sidewall dissection in rectal cancer: case selection and training to optimize outcomes academic.oup.com/bjs/article… @AmyLightnerMD @bplwijn @des_winter @ksoreide @MalinASund @evanscolorectal @nfmkok @robhinchliffe1 @young_bjs
Joe Kong retweeted
Can’t wait for the @MDAndersonNews international rectal cancer symposium tomorrow! Honored to be moderating 3 outstanding and timely rectal cancer debates tomorrow bright & early with Dr. Konishi! @PrajnanDasMD @ColonCancerDoc
Neoadjuvant therapy could be an option for a small subset of patients with a contained perforated colon cancer. Here is our case series and potential benefits. @PeterMacCC @MDAndersonNews @ColonCancerDoc onlinelibrary.wiley.com/doi/… onlinelibrary.wiley.com/doi/… – at Melbourne, Victoria
Joe Kong retweeted
Grad students *should not* be a means to an end to get academic research done.
instead…
Academic research *should* be a means to an end to help students develop the skills and knowledge they need for success in their future careers.
Joe Kong retweeted
MD Anderson is honored to be No. 1 in cancer in @USNews’ annual “Best Hospitals” ranking. We celebrate all who’ve made this possible: our patients and their families, our employees, trainees, donors, volunteers and advocates. bit.ly/3eZKgKM #BestHospitals #EndCancer
Joe Kong retweeted
Great to have #RoLaCaRT 🤖 clinical trial actively underway this week @PeterMacCC … translating innovation to benefits in patient care 🙌 #innovation #surgicaltrials #robotic @JoeCKong @DClark_Brisbane @drkatbristol @DeenaHarji @socroboticsurg @JRobotSurg @ACPGBI @CSSANZ2
Joe Kong retweeted
Really looking forward to the @MDAndersonNews International Symposium on the Surgical Management of Rectal Cancer.
Fantastic talks, cutting edge topics, stellar local and international faculty.
This will be a live webinar on Sept 10th, register below:
mdanderson.cloud-cme.com/cou…
Joe Kong retweeted
For the last day of #MensHealthWeek we're focusing on #bowelcancer. 1 in 11 Aussie men will develop it in their lifetime. Know the signs and if you're over 50, be sure to do your free bowel #cancer screening test when it arrives in the mail. More: health.gov.au/initiatives-an…
Joe Kong retweeted
A 45-year-old today has the same bowel cancer risk a 50-year-old had 10 years ago. The #USPSTF has recommended bowel cancer screening start from age 45.
Lowering the screening age doesn’t address the rise in young-onset bowel cancer - the deadliest cancer for people aged 25-34.
Joe Kong retweeted
In this phase 2 trial randomizing patients with resectable CRC peritoneal metastases to perioperative systemic therapy or surgery & HIPEC alone, perioperative systemic therapy seemed feasible and safe & induced tumor response, justifying a phase 3 trial ja.ma/3eY0zbp
Joe Kong retweeted
An inspirational Tale showing us how research, be it discovery or translational, can one day lead to the development of therapeutics! @slaney_clare, you are a role model for all postdocs in PeterMac! @PeterMacCC @PeterMacRes @NBCFAus
Read here 👉 petermac.org/research/doing-…
Joe Kong retweeted
Very excited to share our latest review discussing T cell persistence in adoptive cell therapies in @NatRevImmunol! Huge effort from our brilliant @jack_chan15 & team @paulbeavis4 @slaney_clare Phil Darcy & Axel Kallies @PeterMacRes
nature.com/articles/s41577-0…
Joe Kong retweeted
March is #ColorectalCancerAwarenessMonth! This is postdoctoral researcher Dr Sara Roth. She is studying colorectal and adenoid cystic carcinoma as part of the MYPHISMO #clinicaltrial which is using a vaccine developed and manufactured by the Ramsay Lab @PeterMacRes.
Joe Kong retweeted
#bloodcancer patients will benefit as @Novartis' CAR T therapy can now be made in Australia, by @CellTherapies_ within Peter Mac. MORE: petermac.org/news/first-comm…
Joe Kong retweeted
Online first: Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for #rectalcancer in the International Watch & Wait Database thelancet.com/journals/lanon…
Joe Kong retweeted
Should elderly patients undergo #colonoscopy surveillance for polyps?
Guideline summary here: polyp.guide/age.html